Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Affimed N.V.    AFMD   NL0010872420


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release: Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares

01/13/2021 | 06:15am EST
   Heidelberg, Germany, January 13, 2021 -- Affimed N.V. ("Affimed" or the 
"Company") (Nasdaq: AFMD), a clinical-stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer, 
today announced the pricing of its previously announced public offering 
of 16,666,667 of its common shares at a public offering price of $6.00 
per common share. In addition, Affimed has granted the underwriters a 
30-day over-allotment option to purchase up to 2,500,000 common shares 
at the public offering price less underwriting discounts. After 
deducting the underwriting discounts, the net proceeds of the public 
offering are expected to be approximately $94 million. The offering is 
expected to close on or about January 15, 2021, subject to customary 
closing conditions. 
   Jefferies LLC, SVB Leerink LLC and Credit Suisse Securities (USA) LLC 
are acting as joint book-running managers and Laidlaw & Company (UK) 
Ltd. is acting as co-manager. A shelf registration statement relating to 
these securities filed with the Securities and Exchange Commission (the 
"SEC") was declared effective by the SEC on December 30, 2020. The 
offering will be made only by means of a prospectus and prospectus 
supplement. A preliminary prospectus supplement and accompanying 
prospectus related to the offering have been filed with the SEC and are 
available at the SEC's website located at 
www.sec.gov. A final prospectus supplement and accompanying prospectus 
will be filed with the SEC. Copies of the preliminary prospectus 
supplement and accompanying prospectus related to the offering may be 
obtained by contacting Jefferies LLC, Attention: Equity Syndicate 
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 
10022, or by telephone at (877) 821-7388 or by email at 
Prospectus_Department@Jefferies.com, SVB Leerink LLC, Attention: 
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, 
by telephone at (800) 808-7525 ext. 6132, or by email at 
syndicate@svbleerink.com, or Credit Suisse Securities (USA) LLC, 
Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, 
NC 27560, by telephone at (800) 221-1037, or by email at 
   This press release shall not constitute an offer to sell or a 
solicitation of an offer to buy, nor shall there be any sale of, these 
securities in any state or jurisdiction in which such offer, 
solicitation or sale would be unlawful prior to registration or 
qualification under the securities laws of any such state or 
   About Affimed N.V. 
   Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer. 
Affimed's fit-for-purpose ROCK(R) platform allows innate cell engagers 
to be designed for specific patient populations. The company is 
developing single and combination therapies to treat hematologic and 
solid tumors. The company is currently enrolling patients into a 
registration-directed study of AFM13 for CD30-positive 
relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a 
dose escalation/expansion study of AFM24 for the treatment of advanced 
EGFR-expressing solid tumors. 
   Forward-looking Statements 
   This press release contains statements that constitute "forward-looking 
statements," including with respect to the proposed offering of common 
shares and the anticipated use of the net proceeds. No assurance can be 
given that the offering discussed above will be completed on the terms 
described, or at all, or that the net proceeds of the offering will be 
used as indicated. Forward-looking statements are subject to numerous 
conditions, many of which are beyond the control of the company, 
including those set forth in the Risk Factors section of the company's 
registration statement and preliminary prospectus for the company's 
offering filed with the Securities and Exchange Commission ("SEC"). 
Copies are available on the SEC's website, 
www.sec.gov. The company undertakes no obligation to update these 
statements for revisions or changes after the date of this release, 
except as required by law. 
   Affimed Investor and Media Contact: 
   Alexander Fudukidis, Head of Investor Relations 
a.fudukidis@affimed.com, IR@affimed.com 
   Tel.: +1 (917) 436-8102 

(END) Dow Jones Newswires

January 13, 2021 06:15 ET (11:15 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
AFFIMED N.V. -0.91% 6.52 Delayed Quote.12.03%
CREDIT SUISSE GROUP AG -0.45% 12.18 Delayed Quote.6.84%
MADISON HOLDINGS GROUP LIMITED -7.56% 0.11 End-of-day quote.-68.57%
NASDAQ COMP. 0.09% 13543.061633 Delayed Quote.4.41%
All news about AFFIMED N.V.
01/15PRESS RELEASE : Affimed Announces Closing of Public Offering of Common Shares an..
01/15Affimed Announces Closing of Public Offering of Common Shares and Full Exerci..
01/13AFFIMED N : Prices 16.7 Million Shares in Public Offering at Discount; Stock Slu..
01/13PRESS RELEASE : Affimed Announces Pricing of $100,000,000 Public Offering of Com..
01/13Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares
01/12AFFIMED N : Kicks off Common Shares offering
01/12PRESS RELEASE : Affimed Announces Proposed Public Offering of Common Shares
01/12Affimed Announces Proposed Public Offering of Common Shares
01/11AFFIMED N : Secures $30.4 Million Debt Financing From Silicon Valley Bank German..
01/11Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference
More news
Sales 2020 32,5 M 39,6 M 39,6 M
Net income 2020 -22,9 M -27,9 M -27,9 M
Net Debt 2020 - - -
P/E ratio 2020 -17,2x
Yield 2020 -
Capitalization 628 M 765 M 765 M
Capi. / Sales 2020 19,3x
Capi. / Sales 2021 19,0x
Nbr of Employees 137
Free-Float 94,6%
Duration : Period :
Affimed N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Average target price 7,95 €
Last Close Price 5,36 €
Spread / Highest target 69,0%
Spread / Average Target 48,4%
Spread / Lowest Target 23,5%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Executive Officer
Thomas O. Hecht Chairman-Supervisory Board
Wolfgang Fischer Chief Operating Officer
Angus W. Smith Chief Financial Officer
Andreas Harstrick Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AFFIMED N.V.12.03%765
WUXI APPTEC CO., LTD.30.64%60 054
BEIGENE, LTD.44.94%32 552